Cargando…
Cabozantinib inhibits HBV-RNA transcription by decreasing STAT3 binding to the enhancer region of cccDNA
BACKGROUND: Precision medicine and customized therapeutics based on the features of each patient are important for maximizing therapeutic effects. Because most cases of HCC occur in the damaged liver through various etiologies, such as hepatitis virus infection, steatohepatitis, and autoimmune hepat...
Autores principales: | Funato, Kazuyoshi, Miyake, Nozomi, Sekiba, Kazuma, Miyakawa, Yu, Seimiya, Takahiro, Shibata, Chikako, Kishikawa, Takahiro, Otsuka, Motoyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635605/ https://www.ncbi.nlm.nih.gov/pubmed/37938099 http://dx.doi.org/10.1097/HC9.0000000000000313 |
Ejemplares similares
-
Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx–DDB1 Interaction
por: Sekiba, Kazuma, et al.
Publicado: (2018) -
Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs
por: Li, Feng, et al.
Publicado: (2016) -
The fatty-acid amide hydrolase inhibitor URB597 inhibits MICA/B shedding
por: Sekiba, Kazuma, et al.
Publicado: (2020) -
The Role of cccDNA in HBV Maintenance
por: Allweiss, Lena, et al.
Publicado: (2017) -
HBV cccDNA: The Stumbling Block for Treatment of HBV Infection
por: Liu, Shousheng, et al.
Publicado: (2019)